Oncosil Medical Limited
1 day chart
Oncosil Medical Limited (OSL, NeuroDiscovery Ltd) is an Australian based and ASX listed medical device company focused on localised treatments for patients with pancreatic and liver cancer. OncoSil's lead product, OncoSil is a first in class medical device with targeted radioactive isotope (Phosphorous-32), implanted directly into a patient's pancreatic tumors via an endoscopic ultrasound. This treatment, known as brachytherapy, is intended to deliver more concentrated and localized radiation.
Buy Australian shares starting with OSL. Invest today with a CHESS-sponsored investing platform!
Life Sciences Tools & Services
What does OncoSil Medical Limited (OSL) do?
Oh, nothing major, just trying to fight cancer.
Headquartered in North Sydney, OncoSil Medical Limited is a medical device company focused on Interventional Oncology (IO), a minimally invasive form of oncology.
The company aims to make life easier for people enduring pancreatic cancer with OncoSil, its flagship brachytherapy device. OncoSil has been designed for implantation directly into a patient’s pancreatic tumours via an endoscopic ultrasound.
Compared to external beam radiotherapy, the OncoSil device can deliver higher doses of radiation while sparing damage to surrounding tissue and critical organs after implantation.
OncoSil Medical took its first step towards revenue generation in October 2020, when it achieved its first sale to a patient in New Zealand. However, COVID-19 disrupted the company’s commercialisation strategy. They're currently hard at work on progressing sales and adoption across Europe, the United States, the Middle East and Asia Pacific.
Is OncoSil Medical a profitable company?
No, OncoSil Medical is not a profitable company.
The company reported revenue of A$213k in FY2021, but prior to this had not earned any revenue since FY2012. The company also recorded net losses between FY2012 and FY2021. In FY2019, FY2020 and FY2021 alone, the company’s net losses amounted to A$8.57m, A$4.26m and A$10.43m, respectively.
As of April 2022, the company holds A$6.6m of cash on its books.
Is OSL stock a buy?
Some investors believe it's a good time to buy OSL stock.
On 13 April 2022, OncoSil Medical announced the first commercial pancreas cancer treatment using the OncoSil device at The Hospital Universitario de Fuenlabrada in Madrid, Spain. The company also announced that ten more hospitals across Spain had been trained to use the OncoSil device. Off this news, the OSL stock price leapt almost 75% from A$0.04 to A$0.07.
However, other investors won’t go near OSL stock for now as the company remains unprofitable and has plenty more regulatory hoops to jump through.
Does OSL stock pay dividends?
OSL stock has no history of distributing dividends. The company has made no announcements to pay dividends this financial year or in the future.
Who owns OSL stock?
At 80.2% of the total float, the general public holds the majority of OSL stock. Individual insiders come second, holding 11.1%.
Some of OSL stock’s most significant owners include Netwealth Investments Ltd (3.04%), Rojo Nero Capital Pty Ltd (2.36%), Gregory Harris (1.98%), Roger Aston (1.6%) and Henderson Family Pty Ltd (1.18%).
Some individual insiders with significant holdings include Non-Executive Director Otto Buttula (3.79%), Global Sales and Marketing Director Michael Warrener (0.88%), CEO Nigel Lange (0.72%), Chairman of the Board Christopher Roberts (0.72%) and CFO Karl Pechmann (0.11%).
How do I buy OSL stock?
Stake offers a quick and easy way to purchase OSL shares – along with 2,000+ other Australian stocks and ASX ETFs – for a brokerage fee of only A$3.
With Stake, you can be in the market in under 5 minutes, whether it's the ASX or Wall St. If you’re interested in building your portfolio by adding OSL, sign up today.
To do so follow these steps:
- Sign up in minutes, all you need is some I.D.
- Choose Stake AUS
- Deposit directly into your Stake wallet and you're ready to invest in OSL
This does not constitute financial advice. You should do your own research before making an investment decision. Past performance is not a reliable indication of future performance. No representation is made as to the timeliness, reliability, accuracy or completeness of the market data provided.